An Egr-1-specific DNAzyme regulates Egr-1 and proliferating cell nuclear antigen expression in rat vascular smooth muscle cells

Experimental and Therapeutic Medicine

Volumn 5, Issue 5, 2013, Pages 1371-1374

  Zhang, Junbiao ^a   Guo, Changlei ^a   Wang, Ran ^a   Huang, Luli ^a   Liang, Wanqian ^a   Liu, Runnan ^b   Sun, Bing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XINXIANG MEDICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Catalytic; DNA; Muscle cells; Proliferating cell nuclear antigen; Serum response factor; Smooth muscle

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CYCLINE; EARLY GROWTH RESPONSE FACTOR 1;

ANIMAL CELL; ARTICLE; ATHEROSCLEROSIS; CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; FLUORESCENCE MICROSCOPY; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSFECTION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; RAT; RESTENOSIS; SMOOTH MUSCLE FIBER; TISSUE ADHESION; WESTERN BLOTTING;

EID: 84876528887     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.1013     Document Type: Article

References (18)

1. Clever YP, Cremers B, Krauss B, et al: Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention 7 (Suppl K): K32-K42, 2011.
2. Nakatani M, Takeyama Y, Shibata M, et al: Mechanisms of restenosis after coronary intervention: difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 12: 40-48, 2003.
3. Yamamoto H, Watanabe T, Miyazaki A, et al: High prevalence of Chlamydia pneumoniae antibodies and increased high-sensitive C-reactive protein in patients with vascular dementia. J Am Geriatr Soc 53: 583-589, 2005.
4. Rhachigian LM: Early growth response-1 in cardiovascular pathobiology. Circ Res 98: 186-191, 2006.
5. Carmi N and Breaker RR: Characterization of a DNA-cleaving deoxyribozyme. Bioorg Med Chem 9: 2589-2600, 2001.
6. Martin MM, Victor X, Zhao X, McDougall JK and Elton TS: Identification and characterization of functional angiotensin II type 1 receptors on immortalized human fetal aortic vascular smooth muscle cells. Mol Cell Endocrinol 183: 81-91, 2001.
7. Cutlip DE, Leon MB, Ho KK, et al: Acute and nine-month clinical outcomes after 'suboptimal' coronary stenting: results from the Stent Anti-thrombotic Regimen Study (STARS) registry. J Am Coll Cardiol 34: 698-706, 1999.
8. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Eng J Med 346: 1773-1780, 2002.
9. Holmes DR Jr, Leon MB, Moses JW, et al: Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 109: 634-640, 2004.
10. Casterella PJ and Teirstein PS: Prevention of coronary restenosis. Cardiol Rev 7: 219-231, 1999.
11. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE and Baim DS: Mechanisms of restenosis and redilatation within coronary stents: quantitative angiographic assessment. J Am Coll Cardiol 21: 1166-1174, 1993.
12. Ohtani K, Egashira K, Usui M, et al: Inhibition of neointimal hyperplasia after balloon injury by cis-element 'decoy' of early growth response gene-1 in hypercholesterolemic rabbits. Gene Ther 11: 126-132, 2004.
13. Santiago FS, Atkins DG and Khachigian LM: Vascular smooth muscle proliferation and regrowth after mechanical injury in vitro are Egr-1/NGFI-A-dependent. Am J Pathol 155: 897-905, 1999.
14. Teng YX, Liu GN and Zhou J: Effect of DNAzyme targeting early growth response factor-1 on endothelial function of injured artery in rats. Journal of China Medical University 34: 511-512, 2005.
15. Han W and Liu GN: EGR-1 decoy ODNs inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia of balloon-injured arteries in rat. Life Sci 86: 234-243, 2010.
16. McArthur JG, Qian H, Citron D, et al: p27-p16 Chimera: a superior antiproliferative for the prevention of neointimal hyperplasia. Mol Therapy 3: 8-13, 2001.
17. Miniati DN, Hoyt EG, Feeley BT, Poston RS and Robbins RC: Ex vivo antisense oligonucleotides to proliferating cell nuclear antigen and Cdc2 kinase inhibit graft coronary artery disease. Circulation 102: 237-242, 2000.
18. Braun-Dullaeus RC, Mann MJ and Dzau VJ: Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98: 82-89, 1998.